JP2022509765A5 - - Google Patents
Info
- Publication number
- JP2022509765A5 JP2022509765A5 JP2021525229A JP2021525229A JP2022509765A5 JP 2022509765 A5 JP2022509765 A5 JP 2022509765A5 JP 2021525229 A JP2021525229 A JP 2021525229A JP 2021525229 A JP2021525229 A JP 2021525229A JP 2022509765 A5 JP2022509765 A5 JP 2022509765A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- enantiomers
- enantiomer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776267P | 2018-12-06 | 2018-12-06 | |
| US62/776,267 | 2018-12-06 | ||
| PCT/IB2019/060454 WO2020115683A1 (en) | 2018-12-06 | 2019-12-04 | 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022509765A JP2022509765A (ja) | 2022-01-24 |
| JP2022509765A5 true JP2022509765A5 (enExample) | 2022-12-12 |
| JP7471291B2 JP7471291B2 (ja) | 2024-04-19 |
Family
ID=68916501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525229A Active JP7471291B2 (ja) | 2018-12-06 | 2019-12-04 | 関節損傷を治療するための軟骨形成を誘導するための５－ヒドロキシ－７－オキサビシクロ［２．２．１］ヘプタン－２－カルボキサミド誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12257243B2 (enExample) |
| EP (1) | EP3891154B1 (enExample) |
| JP (1) | JP7471291B2 (enExample) |
| CN (1) | CN113015735B (enExample) |
| ES (1) | ES2963508T3 (enExample) |
| WO (1) | WO2020115683A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3891155B1 (en) | 2018-12-06 | 2023-08-30 | Novartis AG | 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage |
| CN113015735B (zh) | 2018-12-06 | 2024-06-21 | 诺华股份有限公司 | 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2414623A1 (en) | 2000-08-01 | 2002-02-07 | University Of Virginia Patent Foundation | Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis |
| WO2007130353A2 (en) | 2006-05-01 | 2007-11-15 | Johns Hopkins University | Phase 2 inducers, ppar-alpha agonists and related signalling pathways protect cartilage against inflammation, apoptosis and stress |
| JP5602850B2 (ja) | 2009-07-14 | 2014-10-08 | ザ スクリプス リサーチ インスティテュート | 間葉幹細胞分化 |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| DK3143026T3 (da) * | 2014-05-13 | 2024-09-30 | Novartis Ag | Forbindelser og sammensætninger til induktion af chondrogenese |
| US9745253B2 (en) * | 2015-03-13 | 2017-08-29 | Forma Therapeutics, Inc. | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors |
| UY37759A (es) * | 2017-06-09 | 2019-01-31 | Novartis Ag | Compuestos y composiciones para inducir condrogénesis |
| EP3706710B1 (en) | 2017-11-10 | 2024-04-10 | Novartis AG | Extended release formulations for intra-articular applications |
| CN113015735B (zh) | 2018-12-06 | 2024-06-21 | 诺华股份有限公司 | 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物 |
-
2019
- 2019-12-04 CN CN201980073992.1A patent/CN113015735B/zh active Active
- 2019-12-04 WO PCT/IB2019/060454 patent/WO2020115683A1/en not_active Ceased
- 2019-12-04 JP JP2021525229A patent/JP7471291B2/ja active Active
- 2019-12-04 EP EP19821288.8A patent/EP3891154B1/en active Active
- 2019-12-04 US US17/299,189 patent/US12257243B2/en active Active
- 2019-12-04 ES ES19821288T patent/ES2963508T3/es active Active